While my understanding is that the jury has not yet been seated in Manhattan, I do believe jury selection was completed today. If, by any chance, you (now reading this) are among the jurors, or any alternates, you are required by the Court’s orders and intructions to you, today, to stop reading this.
For the rest of the planet, now, here is Judge Keenan’s final Fosamax® pre-trial order, in relevant part. It offers us a glimpse into the limits on argument, and the limits on admissability of some lines of evidence. I may have a couple more on this trial, in the coming days, if developments warrant:
Consistent with this Court’s policy, the use of the internet in the courtroom during trial is prohibited. . . .
Merck’s request for a Rule 104 hearing on the admissibility of “other risk” evidence offered to rebut Merck’s risk/benefit defense is granted in part. Before plaintiff seeks to offer any evidence of a purported myocardial infarction risk known prior to the date of plaintiff’s injury, the Court will hold a brief hearing outside of the jury’s presence to determine the foundation for such evidence. Plaintiff’s counsel should not refer to this evidence in opening statement.
Plaintiff may offer evidence of an increased fracture risk known prior to the date of plaintiff’s injury. Such evidence is admissible to rebut Merck’s claims about the fracture reduction benefits of Fosamax. Even if otherwise admissible, “other risk” evidence will be circumscribed under Rule 403 to avoid a mini trial on ancillary issues and the danger of jury confusion. This trial is about the risk of ONJ [Ed. Note: osteonecrosis of the jaw).
Merck’s request to exclude all adverse event reports not involving ONJ or exostosis is denied.
Obviously, reports of tongue ulcers, nasal ulcers, or pancreatitis are not relevant or admissible to show that Merck had notice of a risk of ONJ. However; reports describing jaw problems and symptoms consistent with what would later become known as ONJ may be relevant and admissible for the issue of notice. The Court will rule on the admissibility of such reports when they are offered at trial.
Plaintiff’s proposed jury instruction regarding Wyeth v. Levine will not be given. The Court agrees with Merck that the proposed instruction is one-sided and goes beyond the issues discussed by the Supreme Court in Wyeth. If the parties can stipulate to an instruction that will narrow the issues and evidence, they can submit it to the Court for possible use in this or future trials.
The Court acknowledges plaintiff’s agreement not to offer evidence of Japanese causality assessments. The Court rules that plaintiff may not offer evidence of the 2002 ONJ report with Onclast because plaintiff has not established that any Merck entity received the report prior to the date of plaintiff’ a injury. Therefore, there is no foundation to admit the evidence for the issue of notice.
Copies of the Court’s jury selection procedure will be faxed to counsel this afternoon.
/s/ Judge John F. Keenan
August 10, 2009
Filed In Associated Cases: 1:06-md-01789-JFK-JCF, 1:06-cv-09455-JFK. . . .
Now — let the games begin, in earnest.